bioRxiv Science⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2025.09.16.676615

An increased number of heterozygous calls in the AxiomTM Equine Genotyping Array

Neuditschko, M.·Gmel, A. I.·Pirani, A.·McInnis, L.
View original source ↗Export metadata ↓

Abstract

Single nucleotide polymorphism (SNP) arrays are commonly used in livestock genetics to investigate complex traits including genome-wide analysis and fine mapping, genomic prediction, genetic diversity and selection signature analyses. In the context of a European Equine diversity study, we analysed the Axiom Equine 670K SNP genotype data from 2,768 equids representing 20 horse breeds and one donkey breed. While assessing genome-wide runs of homozygosity (ROH) patterns, we observed an increased number of heterozygous calls in 167 purebred horses, which exhibited fewer ROH segments compared to F1 crosses, with 24 of them completely lacking any ROH segments. To further investigate this, we conducted a 4-fold genotype concordance analysis of replicate pairs on the same Axiom batch, between two different Axiom batches, between Illumina EquineSNP50 BeadChip(R) and between Illumina paired-end HiSeq 2000 whole genome sequencing data. Additionally, we used SNPolisher classification on data from the Axiom Equine 670K SNP array to evaluate the genotype performance of the 670,806 genome-wide SNPs. When comparing the overlapping SNPs between the different genotyping platforms, replicated pairs within the same Axiom batch showed the highest average genotype concordance (98.81%), followed by Illumina 50K (97.88%) and whole genome sequencing (96.84%). In contrast, re-genotyped horses with few ROH segments (i.e., replicates on different batches) showed the lowest concordance (93.52%). A lower pass rate was observed in one batch, suggesting a processing performance issue that contributed to the reduced concordance between batches. According to SNPolisher classification a total of 120,838 genome-wide SNPs were not recommended for reproducibility. After calling genotypes of the two different batches together in accordance with Axiom Best Practice (e.g. removing failing samples before the final genotyping) and excluding non-recommended SNPs, genotype concordance improved in all comparisons: same Axiom batch (99.84%), Illumina 50K (98.33%), whole genome sequencing (97.81%), and different Axiom batches (98.59%). Based on these findings, we recommend excluding horses exhibiting an unusually high number of heterozygous calls, using only SNPs with validated genotype performance, and accounting for batch effects when analyzing Axiom Equine 670K SNP genotype data from different batches. Article SummaryIn a European Equine diversity study including over 2,000 equids from 20 horse breeds and one donkey breed, we detected an unusually high number of heterozygous calls using the Axiom Equine 670K SNP array. Genotype concordance testing across different platforms showed that horses with fewer runs of homozygosity (ROH) had notably lower genotype concordance rates. By applying Axiom Best Practices and excluding SNPs with poor reproducibility, genotype concordance significantly improved. These findings highlight the critical need to validate SNP quality to ensure reliable genotypes for equine genomics projects and to account for batch effects when analyzing SNP data from different Axiom batches.

Explore related subjects

genomicsPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Neuditschko, M., Gmel, A. I., Pirani, A., McInnis, L.. 2025-09-18. An increased number of heterozygous calls in the AxiomTM Equine Genotyping Array. https://doi.org/10.1101/2025.09.16.676615

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

PfPHAST: Plasmodium falciparum Public Health Amplicon Sequencing Tool, a Streamlined Panel for Malaria Genomic Surveillance

Genomic tools can support malaria control policy through surveillance of Plasmodium falciparum populations, tracking antimalarial drug resistance, pfhrp2/3 deletions that compromise rapid diagnostic tests, and selection at the circumsporozoite protein (PfCSP) vaccine target, as well as through molecular correction of therapeutic efficacy studies (TES). Multiplex Amplicons for Drug, Diagnostic, Diversity, and Differentiation Haplotypes using Targeted Resequencing (MAD4HatTeR), a comprehensive amplicon sequencing panel covering up to 276 targets, supports these applications but is tailored to research rather than routine programmatic use. We developed P. falciparum Public Health Amplicon Sequencing Tool (PfPHAST), a 56-target derivative of MAD4HatTeR spanning drug resistance loci, pfhrp2/3 deletion, PfCSP genotyping, non-falciparum species identification, and 20 high-heterozygosity microhaplotype loci for TES classification. We compared PfPHAST and MAD4HatTeR using laboratory strain controls, including two-strain dilution series and a five-strain mixture, across parasite densities of 100 to 10,000 parasites/L. At matched per-target depth, PfPHAST achieved a higher quality-control pass rate than MAD4HatTeR (94.4% versus 90.0%) and distributed reads more evenly across targets. The panels showed comparable recall and precision for drug resistance codons and microhaplotypes, reaching near-complete recall above 40% within-sample allele frequency (WSAF) at all densities, with reduced sensitivity for minor alleles below 10% WSAF at low parasite density in both panels. Observed and expected WSAF correlated strongly for both panels, and both resolved a five-strain polyclonal mixture, including a 5% minor strain. By concentrating sequencing capacity on targets of greatest programmatic relevance, PfPHAST offers a scalable, lower-cost alternative to comprehensive research panels without sacrificing performance on shared targets, complementing MAD4HatTeR for routine molecular malaria surveillance.

genomics↗
bioRxiv2026

Structural variation in repeat elements is widespread in normal human tissues and in tumorigenesis

Somatic mosaicism contributes to genomic variation, yet postzygotic structural variants remain under-characterized. We performed long- and short-read WGS from multiple individuals (n=47 normal tissues; n=168 samples) and identified mosaic structural variants in all individuals and germ layers, impacting a median 285.2 kb/genome. Nearly half of breakpoints were independently validated, with tissue distributions reflecting both early and late developmental origins. Most mosaic variants were repeat-mediated and 8.3% overlapped functional elements, an enrichment compared to germline variants. To extend these analyses in samples where long-read sequencing is infeasible, we measured repeat alterations from short-read sequencing, recapitulating mosaic tissue-specific differences. We characterized tumor- and tissue- specific variation in repeats across 15 cancer types and found tumor-related repeat variation to be similar in scale to that of normal mosaic variation. Tracking repeat changes in cell-free DNA provided a noninvasive approach for tumor monitoring. Our analyses revealed widespread repeat-driven structural variation in health and disease.

genomics↗
bioRxiv2026

RNA isoform-resolved multiplexed sequencing with bioorthogonal barcoding

RNA isoform dysregulation drives disease pathogenesis and is the target of FDA-approved splice-switching therapeutics. However, multiplexed sequencing methods discard splice junction information because only 3' termini are barcoded and counted. Here, we repurpose acylation and click chemistries to conjugate bioorthogonal barcodes (bobcodes) directly onto multiple internal positions along cellular RNAs. Bobcoded RNAs from multiple samples are pooled for multiplexed cDNA synthesis, during which reverse transcriptase switches from each RNA template onto its tethered bobcode with greater than 99% accuracy in species mixing experiments. Bobcode attachment intervals set cDNA insert sizes without a library fragmentation step, and priming with poly(dT) or random hexamers selects between 3'-end counting and full-length isoform capture. A bioorthogonal barcode-sequencing (BOB-seq v0.1) drug screen identifies transcriptome-wide on- and off-target RNA splicing effects and outperforms existing multiplexing RNA sequencing methods in workflow simplicity, sample-to-sample variability, and barcoding accuracy. Bobcodes add isoform resolution to scalable multiplexed RNA sequencing.

genomics↗